Frank Clyburn to Leave Merck
20 Januar 2022 - 12:45PM
Business Wire
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, announced today that Frank Clyburn, executive vice
president and president, Human Health, will leave Merck on Feb. 1,
2022, to assume a leadership opportunity with another company.
Leadership of Human Health following Frank’s departure will be
announced in the coming weeks.
“I am extremely appreciative of Frank’s significant
contributions to our company during his fourteen years with Merck.
Frank has been a key catalyst for value creation, an incredible
business strategist, a dedicated people leader and a fierce
advocate for patients everywhere,” said Robert M. Davis, chief
executive officer and president, Merck. “Frank’s strategic and
operational excellence helped establish Merck as a global leader in
oncology. Our human health business has delivered strong and
sustainable growth under Frank’s leadership, and we are
well-positioned to continue this momentum with the strong human
health team we have in place.”
Clyburn joined Merck in 2008 and held several leadership
positions with increasing responsibility throughout his Merck
career. In March 2021, Clyburn was named president of Human Health.
Previously, Clyburn served as chief commercial officer for Human
Health, and was the president of Merck’s global oncology business.
During his time at Merck, he also managed multiple global
pharmaceutical franchises, including diabetes, cardiovascular and
women’s health, and led numerous marketing and sales teams.
About Merck
For over 130 years, Merck, known as MSD outside the United
States and Canada, has been inventing for life, bringing forward
medicines and vaccines for many of the world’s most challenging
diseases in pursuit of our mission to save and improve lives. We
demonstrate our commitment to patients and population health by
increasing access to health care through far-reaching policies,
programs and partnerships. Today, Merck continues to be at the
forefront of research to prevent and treat diseases that threaten
people and animals – including cancer, infectious diseases such as
HIV and Ebola, and emerging animal diseases – as we aspire to be
the premier research-intensive biopharmaceutical company in the
world. For more information, visit www.merck.com and connect with
us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of the global outbreak of novel coronavirus disease
(COVID-19); the impact of pharmaceutical industry regulation and
health care legislation in the United States and internationally;
global trends toward health care cost containment; technological
advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining
regulatory approval; the company’s ability to accurately predict
future market conditions; manufacturing difficulties or delays;
financial instability of international economies and sovereign
risk; dependence on the effectiveness of the company’s patents and
other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2020
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220120005357/en/
Media Contacts: Melissa Moody (215) 407-3536 Johanna Herrmann
(617) 216-6029 Investor Contacts: Peter Dannenbaum (908) 740-1037
Steve Graziano (908) 740-6582
Merck (NYSE:MRK)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
Von Apr 2023 bis Apr 2024